latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/sinovac-sinopharm-covid-19-vaccines-approved-for-china-emergency-use-8211-reuters-60125970 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sinovac, Sinopharm COVID-19 vaccines approved for China emergency use – Reuters

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Sinovac, Sinopharm COVID-19 vaccines approved for China emergency use – Reuters

Sinovac Biotech Ltd.'s COVID-19 vaccine candidate was authorized for emergency use in China under a program to immunize high-risk populations, including medical frontliners, Reuters reported Aug. 28.

Also, China National Biotec Group Co. Ltd., a unit of state-owned Sinopharm Group Co. Ltd. received emergency use authorization for a coronavirus vaccine, the report noted, citing a company announcement on social media app WeChat.

The Chinese government rolled out the vaccination program in July, Reuters added. A local health official told state media that authorities are eyeing modestly expanding the emergency use program to prevent potential outbreaks in the autumn and winter.

In June, Chinese media reported that staff at state-owned companies who need to travel abroad could receive one of the two vaccine candidates being assessed by China National Biotec in late-stage studies. Meanwhile, CanSino Biologics Inc.'s vaccine has been cleared for use by China's military, the report added.

Shanghai Junshi Biosciences Co. Ltd. and Alphamab Oncology are also among Chinese companies developing a vaccine for the coronavirus.

As of Aug. 28, China has reported more than 89,800 confirmed cases of COVID-19, with the death toll reaching 4,700, data from Johns Hopkins University's Center for Systems Science and Engineering showed. Worldwide, there have been over 24.4 million people infected with the coronavirus, resulting in at least 832,400 deaths.

SNL Image

READ MORE: Sign up for our weekly coronavirus newsletter here, and read our latest coverage on the crisis here.